{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:33:44Z","timestamp":1794666824614,"version":"4.9.1"},"reference-count":14,"publisher":"BMJ","issue":"14","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2017,11,28]]},"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive adult patients with CHD\u2013PAH received subcutaneous treprostinil to maximum tolerated doses in an observational study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Advanced CHD\u2013PAH patients with WHO class III or IV disease (n=32, age 40\u00b110 years, 20 females) received treprostinil for suboptimal response to bosentan (n=12), WHO functional class IV disease (FC, n=7) or prior to bosentan approval (n=13). In the multivariate mixed model, mean increase in 6\u2009min walk distance (6-MWD) from baseline to 12 months was 114\u2009m (76; 152) (P&lt;0.001). WHO FC improved significantly (P=0.001) and B-type brain natriuretic peptide decreased from 1259 (375; 2368) pg\/mL to 380 (144; 1468) pg\/mL (P=0.02). In those 14 patients who had haemodynamic data before and after initiation of treprostinil, pulmonary vascular resistance decreased significantly (from 18.4\u00b111.1\u2009to 12.6\u00b17.9 Wood units, P=0.003). The most common adverse events were infusion-site erythema and pain. One patient stopped treatment because of intolerable infusion-site pain after 8 months of treatment. No other major treatment-related complications were observed. Five patients died during early follow-up, having experienced a decrease in their 6-MWD prior.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Subcutaneous treprostinil therapy is generally safe and effective for at least 12 months and may be used in CHD-related PAH class III and IV.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2017-312143","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T12:20:13Z","timestamp":1518006013000},"page":"1195-1199","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension"],"prefix":"10.1136","volume":"104","author":[{"given":"Nika","family":"Skoro-Sajer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gerges","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Hajnalka","family":"Balint","sequence":"additional","affiliation":[{"name":"Gy\u00f6rgy Gottsegen, Hungarian Institute of Cardiology, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Kohalmi","sequence":"additional","affiliation":[{"name":"Gy\u00f6rgy Gottsegen, Hungarian Institute of Cardiology, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kaldararova","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Slovak Medical University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iveta","family":"Simkova","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Slovak Medical University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Jakowitsch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gerges","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roela","family":"Sadushi-Kolici","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Celermajer","sequence":"additional","affiliation":[{"name":"Sydney Medical School, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Marthe","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"2025092015010660000_104.14.1195.1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-005-4264-9"},{"key":"2025092015010660000_104.14.1195.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2025092015010660000_104.14.1195.3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.acvd.2017.01.006","article-title":"Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: a french multicentre study","volume":"110","author":"Hascoet","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"2025092015010660000_104.14.1195.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.630715"},{"key":"2025092015010660000_104.14.1195.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2025092015010660000_104.14.1195.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv743"},{"key":"2025092015010660000_104.14.1195.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2025092015010660000_104.14.1195.8","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.14.1858"},{"key":"2025092015010660000_104.14.1195.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2012.02.025"},{"key":"2025092015010660000_104.14.1195.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02394.x"},{"key":"2025092015010660000_104.14.1195.11","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx493.P5462","article-title":"P5462Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomised controlled MAESTRO study","volume":"38","author":"Galie","year":"2017","journal-title":"Eur Heart J"},{"key":"2025092015010660000_104.14.1195.12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijcard.2017.05.101","article-title":"Mortality in pulmonary arterial hypertension due to congenital heart disease: Serial changes improve prognostication","volume":"243","author":"Schuijt","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025092015010660000_104.14.1195.13","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.ijcard.2013.07.072","article-title":"Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease","volume":"168","author":"Thomas","year":"2013","journal-title":"Int J Cardiol"},{"key":"2025092015010660000_104.14.1195.14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1183\/09031936.99.13613579","article-title":"Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study","volume":"13","author":"Humbert","year":"1999","journal-title":"Eur Respir J"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-312143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T22:01:13Z","timestamp":1758405673000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-312143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":14,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2018,6,26]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/heartjnl-2017-312143"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-312143","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}